CONMED (NYSE:CNMD – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Volatility and Risk
CONMED has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.
Institutional & Insider Ownership
55.5% of Sight Sciences shares are owned by institutional investors. 0.3% of CONMED shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CONMED | $1.37 billion | 1.12 | $47.06 million | $2.42 | 21.36 |
| Sight Sciences | $88.39 million | 6.52 | -$38.43 million | ($0.52) | -20.12 |
CONMED has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CONMED and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CONMED | 5.36% | 13.93% | 6.26% |
| Sight Sciences | -32.13% | -43.91% | -22.20% |
Analyst Recommendations
This is a summary of current recommendations and price targets for CONMED and Sight Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CONMED | 1 | 7 | 0 | 0 | 1.88 |
| Sight Sciences | 1 | 2 | 5 | 0 | 2.50 |
CONMED presently has a consensus price target of $44.00, indicating a potential downside of 14.89%. Sight Sciences has a consensus price target of $9.62, indicating a potential downside of 8.03%. Given Sight Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than CONMED.
About CONMED
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.
